Photorefractive keratectomy for compound myopic astigmatism

Am J Ophthalmol. 2000 Jul;130(1):12-9. doi: 10.1016/s0002-9394(00)00400-1.

Abstract

Purpose: To evaluate the safety and efficacy of photorefractive keratectomy for the treatment of primary compound myopic astigmatism.

Methods: In a prospective study, 93 eyes from 56 patients with a mean spherical equivalent of -4.98 +/- 1.80 diopters (range, -1.75 to -8.5) underwent photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser using erodible mask technology and were followed for 2 years. Primary outcome measures included an assessment of astigmatic correction through vector analysis, manifest refraction, uncorrected visual acuity, corneal clarity, and the presence of adverse symptoms.

Results: Eighty-five eyes (91.4%) were available for analysis at 6 months. Mean spherical equivalent refraction was reduced 85% (mean, -0.75 +/- 0.85 diopter) and the target-induced astigmatism was reduced 70% (mean, 0.98 +/- 1.88 diopters). Forty-eight eyes (56%) had an uncorrected visual acuity of 20/20 or greater, whereas 70 eyes (82%) had an uncorrected visual acuity of 20/40 or greater. Twenty-four eyes (26% ) required re-treatment because of undercorrection of the spherical equivalent and astigmatic components after the 6-month follow-up. Fifty-nine of the remaining eyes were available at the 24-month visit. Mean spherical equivalent refraction was reduced to -0.39 +/- 0.72 diopter (91.8%). The target-induced astigmatism was reduced 64% from 1.74 diopters. Forty-one eyes (81.3%) were within +/-1.0 diopter of attempted spherical equivalent correction. Stability within a spherical equivalent of +/-0.5 diopter occurred after the first postoperative month. Fifty-six eyes (94.9%) had an uncorrected visual acuity of 20/40 or greater, whereas 34 eyes (57.6 %) demonstrated an uncorrected visual acuity of 20/20 or greater. One eye (1.7%) lost 2 or more lines of best spectacle-corrected visual acuity.

Conclusion: Photoastigmatic refractive keratectomy with the Summit Apex Plus excimer laser is a safe and effective method of reducing compound myopic astigmatism. However, higher re-treatment rates may result from significant undercorrections because of current laser algorithms and variability in the mean angle of error.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Astigmatism / surgery*
  • Cornea / surgery*
  • Female
  • Follow-Up Studies
  • Humans
  • Lasers, Excimer
  • Male
  • Middle Aged
  • Myopia / surgery*
  • Photorefractive Keratectomy*
  • Postoperative Complications
  • Prospective Studies
  • Refraction, Ocular
  • Reoperation
  • Safety
  • Treatment Outcome
  • Visual Acuity